KR920019734A - Phenylsulfonylalkanoic acid compound - Google Patents

Phenylsulfonylalkanoic acid compound Download PDF

Info

Publication number
KR920019734A
KR920019734A KR1019910006078A KR910006078A KR920019734A KR 920019734 A KR920019734 A KR 920019734A KR 1019910006078 A KR1019910006078 A KR 1019910006078A KR 910006078 A KR910006078 A KR 910006078A KR 920019734 A KR920019734 A KR 920019734A
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl group
group
formula
compound
Prior art date
Application number
KR1019910006078A
Other languages
Korean (ko)
Inventor
마끼오 기다자와
마쓰오 아까하네
야쓰시 나까노
아쓰시 쓰바끼
가즈아끼 사또오
마사아끼 반
미찌히로 고바야시
Original Assignee
간자와 구니오
깃세이 야꾸힝 고오교오 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 간자와 구니오, 깃세이 야꾸힝 고오교오 가부시끼가이샤 filed Critical 간자와 구니오
Priority to KR1019910006078A priority Critical patent/KR920019734A/en
Publication of KR920019734A publication Critical patent/KR920019734A/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음No content

Description

페닐술포닐알칸산 화합물Phenylsulfonylalkanoic acid compound

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

하기식의 화합물 및 그의 제약적 허용염 :Compounds of the formula and pharmaceutically acceptable salts thereof: 식중, R1은 탄소수가 1 내지 10인 알킬기, 탄소수가 3 내지 7인 알콕시 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R2는 탄소수가 1 내지 10인 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R3는 탄소수 1 내지 4인 수소원자 또는 알킬기를 나타내고 ; X는 할로겐원자, 탄소수가 1 내지 3인 알킬기, 나트로기 또는 아세틸기를 나타내고 ; m은 1 내지 3인 정수이고 ; n은 1 또는 2이다.In the formula, R 1 represents an alkyl group having 1 to 10 carbon atoms, an alkoxy alkyl group having 3 to 7 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 2 represents an alkyl group having 1 to 10 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; X represents a halogen atom, an alkyl group having 1 to 3 carbon atoms, a natro group or an acetyl group; m is an integer of 1 to 3; n is 1 or 2. 제1항에 있어서, X는 할로겐 원자인 것을 특징으로 하는 화합물.A compound according to claim 1, wherein X is a halogen atom. 제1항에 있어서, m은 2인 것을 특징으로 하는 화합물.The compound of claim 1, wherein m is 2. 제1항에 있어서, R2는 탄소수가 1 내지 10인 알킬기인 것을 특징으로 하는 화합물.The compound according to claim 1, wherein R 2 is an alkyl group having 1 to 10 carbon atoms. 제1항에 있어서, R1는 탄소수가 3 내지 7인 알콕시알킬기인 것을 특징으로 하는 화합물.A compound according to claim 1, wherein R 1 is an alkoxyalkyl group having 3 to 7 carbon atoms. 제1항에 있어서, R3이 수소원자인 것을 특징으로 하는 화합물.A compound according to claim 1, wherein R 3 is a hydrogen atom. 하기식의 화합물 및 그의 제약적 허용염.Compounds of the formula and pharmaceutically acceptable salts thereof. 제1항의 페닐술포닐알칸산 화합물 또는 그의 제약적 허용염을 활성 성분으로 함유하는 것을 특징으로 하는 제약적 조성물.A pharmaceutical composition comprising the phenylsulfonylalkanoic acid compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient. 하기식의 화합물 ;Compound of the following formula; 식중, R1은 탄소수가 1 내지 10인 알킬기, 탄소수가 3 내지 7인 알콕시 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R2는 탄소수가 1 내지 10인 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R4는 탄소수 1 내지 4인 알킬기를 나타내고 ; X는 할로겐원자, 탄소수가 1 내지 3인 알킬기, 나트로기 또는 아세틸기를 나타내고 ; m은 1 내지 3인 정수이고 ; n은 1 또는 2이다.In the formula, R 1 represents an alkyl group having 1 to 10 carbon atoms, an alkoxy alkyl group having 3 to 7 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 2 represents an alkyl group having 1 to 10 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 4 represents an alkyl group having 1 to 4 carbon atoms; X represents a halogen atom, an alkyl group having 1 to 3 carbon atoms, a natro group or an acetyl group; m is an integer of 1 to 3; n is 1 or 2. 하기식의 화합물 :Compound of the formula 식중, R1은 탄소수가 1 내지 10인 알킬기, 탄소수가 3 내지 7인 알콕시 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R2는 탄소수가 1 내지 10인 알킬기 또는 탄소수가 7 내지 12인 아르알킬기를 나타내고 ; R4는 탄소수 1 내지 4인 알킬기를 나타내고 ; X는 할로겐원자, 탄소수가 1 내지 3인 알킬기, 나트로기 또는 아세틸기를 나타내고 ; m은 1 내지 3인 정수이고 ; n은 1 또는 2이다.In the formula, R 1 represents an alkyl group having 1 to 10 carbon atoms, an alkoxy alkyl group having 3 to 7 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 2 represents an alkyl group having 1 to 10 carbon atoms or an aralkyl group having 7 to 12 carbon atoms; R 4 represents an alkyl group having 1 to 4 carbon atoms; X represents a halogen atom, an alkyl group having 1 to 3 carbon atoms, a natro group or an acetyl group; m is an integer of 1 to 3; n is 1 or 2. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019910006078A 1991-04-16 1991-04-16 Phenylsulfonylalkanoic acid compound KR920019734A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019910006078A KR920019734A (en) 1991-04-16 1991-04-16 Phenylsulfonylalkanoic acid compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019910006078A KR920019734A (en) 1991-04-16 1991-04-16 Phenylsulfonylalkanoic acid compound

Publications (1)

Publication Number Publication Date
KR920019734A true KR920019734A (en) 1992-11-19

Family

ID=67432656

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910006078A KR920019734A (en) 1991-04-16 1991-04-16 Phenylsulfonylalkanoic acid compound

Country Status (1)

Country Link
KR (1) KR920019734A (en)

Similar Documents

Publication Publication Date Title
DE69415445D1 (en) Cytotoxic stilbene derivatives and pharmaceutical compositions containing them
KR950016737A (en) Inhibition of symptoms of premenstrual syndrome / late luteal phase unpleasant disease
KR900006296A (en) Imidazoline derivatives and preparation method thereof
KR960007592A (en) New pyrrolocarbazole
KR960706472A (en) Prostaglandin derivatives, salts thereof and use thereof
KR900001643A (en) Antibacterial agents
KR890011596A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for treating insomnia
KR930703292A (en) Novel quinolone derivatives or salts thereof and antimicrobial agents containing the compounds
KR920016089A (en) Treatment of Type I Diabetes
KR950702530A (en) Prostaglandin derivatives
KR920007995A (en) Benzamide derivatives
KR900016178A (en) 2-substituted N, N'-ditrimethoxybenzoyl piperazine, preparation method thereof and therapeutic composition containing the same
KR890008148A (en) New Sepharoseporin Compounds and Antibacterials
KR890006639A (en) Benzothiazine dioxide derivatives
KR920005986A (en) Pharmaceutical composition for inhibiting platelet aggregation
MX9206930A (en) NEW COMPOUNDS
KR960700245A (en) Methotrexate derivative [METHOTREXATE DERIVATIVE]
KR900006316A (en) Benzo heterocyclic compound and preparation method thereof
KR920019734A (en) Phenylsulfonylalkanoic acid compound
KR850005228A (en) Aminoalkanosephosphonic acid and its derivatives as fungicides
KR910005860A (en) Anti Liver Disease Composition
KR950704252A (en) N-substituted imidazole derivatives
KR890002079A (en) 1- [2- (phenylmethyl) phenyl] piperazine and preparation method thereof
KR900016144A (en) 4-imidazoline derivative
KR900700104A (en) Anti-anxiety

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination